OHI · Omega Healthcare Investors Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $322.95M | - | $311.59M | $282.51M | $276.79M | - | $276.03M | $252.75M | $243.30M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $26.02M | - | $23.78M | $23.84M | $32.06M | - | $21.76M | $22.15M | $21.53M | - |
| Total Operating Expenses | $167.14M | - | $165.34M | $171.95M | $175.31M | - | $163.26M | $149.89M | $174.07M | - |
| D&A | $84.14M | - | $82.11M | $80.51M | $79.88M | - | $77.25M | $74.23M | $74.56M | - |
| Operating Income | $159.92M | - | $191.35M | $147.19M | $114.59M | - | $111.35M | $118.92M | $71.83M | - |
| Interest Expense | $49.76M | - | $58.12M | $52.90M | $52.28M | - | $54.69M | $53.97M | $57.82M | - |
| Income Tax | $5.11M | - | $4.48M | $4.53M | $3.61M | - | $3.32M | $1.98M | $2.58M | - |
| Net Income | $151.05M | - | $111.76M | $136.60M | $67.36M | - | $111.76M | $113.86M | $67.36M | - |
| EPS - Basic | $0.47 | - | $0.60 | $0.46 | $0.34 | - | $0.43 | $0.46 | $0.27 | - |
| EPS - Diluted | $0.47 | - | $0.59 | $0.46 | $0.33 | - | $0.42 | $0.45 | $0.27 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.15M | $27.02M | $737.19M | $734.18M | $367.96M | $518.34M | $342.44M | $35.19M | $361.77M | $442.81M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | - | - | - | - | - | - | - | - | - | - |
| Total Assets | $10.23B | $10.05B | $10.60B | $10.55B | $9.71B | $9.90B | $9.57B | $8.85B | $9.01B | $9.12B |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - |
| Long-term Debt | - | $4.26B | $4.99B | $5.00B | $4.45B | $4.84B | $4.86B | $4.66B | $5.03B | $5.07B |
| Total Liabilities | $4.78B | $4.61B | $5.35B | $5.36B | $4.77B | $5.17B | $5.17B | $4.95B | $5.31B | $5.36B |
| Stockholders' Equity | $5.19B | $5.18B | $5.04B | $4.99B | $4.74B | $4.54B | $4.21B | $3.71B | $3.51B | $3.57B |
| Retained Earnings | $4.83B | $4.68B | $4.51B | $4.33B | $4.20B | $4.09B | $3.97B | $3.86B | $3.75B | $3.68B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $215.50M | - | - | - | $181.95M | - | - | - | $151.47M | - |
| Investing Cash Flow | ($270.01M) | - | - | - | $19.26M | - | - | - | ($47.45M) | - |
| Financing Cash Flow | $54.32M | - | - | - | ($347.70M) | - | - | - | ($186.02M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 49.5% | - | 61.4% | 52.1% | 41.4% | - | 40.3% | 47.1% | 29.5% | - |
| EBITDA margin | 75.6% | - | 87.8% | 80.6% | 70.3% | - | 68.3% | 76.4% | 60.2% | - |
| Net margin | 46.8% | - | 35.9% | 48.4% | 24.3% | - | 40.5% | 45.1% | 27.7% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 8.1% | - | 7.6% | 8.4% | 11.6% | - | 7.9% | 8.8% | 8.9% | - |
| Effective tax rate | 3.3% | - | 3.9% | 3.2% | 5.1% | - | 2.9% | 1.7% | 3.7% | - |
| Return on assets | 1.5% | - | 1.1% | 1.3% | 0.7% | - | 1.2% | 1.3% | 0.7% | - |
| Return on equity | 2.9% | - | 2.2% | 2.7% | 1.4% | - | 2.7% | 3.1% | 1.9% | - |
| Return on invested capital | - | - | 1.8% | 1.4% | 1.2% | - | 1.2% | 1.4% | 0.8% | - |
| Liquidity | ||||||||||
| Current ratio | - | - | - | - | - | - | - | - | - | - |
| Quick ratio | - | - | - | - | - | - | - | - | - | - |
| Cash ratio | - | - | - | - | - | - | - | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | - | 0.82 | 0.99 | 1.00 | 0.94 | 1.07 | 1.15 | 1.26 | 1.43 | 1.42 |
| Debt / Assets | - | 0.42 | 0.47 | 0.47 | 0.46 | 0.49 | 0.51 | 0.53 | 0.56 | 0.56 |
| Debt / EBITDA | - | - | 18.26 | 21.96 | 22.86 | - | 25.76 | 24.13 | 34.35 | - |
| Interest coverage | 3.2x | - | 3.3x | 2.8x | 2.2x | - | 2.0x | 2.2x | 1.2x | - |
| Equity multiplier | 1.97 | 1.94 | 2.10 | 2.11 | 2.05 | 2.18 | 2.27 | 2.38 | 2.56 | 2.55 |
| Liabilities / Assets | 0.47 | 0.46 | 0.51 | 0.51 | 0.49 | 0.52 | 0.54 | 0.56 | 0.59 | 0.59 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.03 | 0.03 | 0.03 | - | 0.03 | 0.03 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 93.2x | - | 71.6x | 79.7x | 115.4x | - | 96.9x | 76.1x | 117.3x | - |
| P / B | 2.7x | - | 2.6x | 2.2x | 2.4x | - | 2.7x | 2.4x | 2.3x | - |
| P / S | 42.8x | - | 41.8x | 39.3x | 40.6x | - | 40.6x | 35.4x | 33.5x | - |
| EV / EBITDA | 56.5x | - | 63.1x | 67.5x | 78.7x | - | 83.4x | 70.3x | 87.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 16.7% | - | 12.9% | 11.8% | 13.8% | - | 14.0% | 1.0% | 11.5% | - |
| Revenue CAGR (3y) | 14.0% | - | 9.2% | 4.9% | 3.5% | - | -0.7% | -0.6% | -3.9% | - |
| Revenue CAGR (5y) | 3.4% | - | 21.2% | 2.0% | 1.8% | - | 3.4% | 2.3% | 1.7% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 39.6% | - | 71.8% | 23.8% | 59.5% | - | 14.8% | 91.6% | 106.9% | - |
| Net income growth (YoY) | 124.2% | - | 0.0% | 20.0% | 0.0% | - | 22.3% | 90.2% | 87.4% | - |
| EPS growth (YoY) | 42.4% | - | 40.5% | 2.2% | 22.2% | - | 13.5% | 80.0% | 80.0% | - |
| EPS CAGR (3y) | 46.3% | - | 11.1% | 6.6% | -25.2% | - | -10.2% | 7.7% | -26.9% | - |
| EPS CAGR (5y) | -7.4% | - | - | 1.4% | -3.3% | - | -7.8% | 5.8% | -4.5% | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 9.5% | 14.2% | 19.7% | 34.4% | 34.9% | 26.9% | 14.7% | 2.4% | 0.5% | -1.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$180.10M totalGB$180.10M · 100.0%
Peer comparison
Same SIC group: Real Estate Investment Trusts
Comparing OMEGA HEALTHCARE INVESTORS INC against the 5 most active filers in the same SIC group.
Dividends
$2.68/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 4, 2026 | $0.6700 |
| Feb 9, 2026 | $0.6700 |
| Nov 3, 2025 | $0.6700 |
| Aug 4, 2025 | $0.6700 |
| May 5, 2025 | $0.6700 |
| Feb 10, 2025 | $0.6700 |
| Nov 4, 2024 | $0.6700 |
| Aug 5, 2024 | $0.6700 |
| Apr 29, 2024 | $0.6700 |
| Feb 2, 2024 | $0.6700 |
| Oct 30, 2023 | $0.6700 |
| Jul 28, 2023 | $0.6700 |
| Apr 28, 2023 | $0.6700 |
| Feb 3, 2023 | $0.6700 |
| Oct 31, 2022 | $0.6700 |
| Jul 29, 2022 | $0.6700 |
| Apr 29, 2022 | $0.6700 |
| Feb 4, 2022 | $0.6700 |
| Nov 4, 2021 | $0.6700 |
| Jul 30, 2021 | $0.6700 |
| Apr 30, 2021 | $0.6700 |
| Feb 5, 2021 | $0.6700 |
| Oct 30, 2020 | $0.6700 |
| Jul 30, 2020 | $0.6700 |